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Background
A few days of glucocorticoid intake has been shown to improve performance during 
submaximal exercise (Le Panse et  al. 2009; Collomp et  al. 2008; Arlettaz et  al. 2007). 
Thus, under current World Anti-Doping Agency (WADA) legislation, all glucocorticoids 
are prohibited in-competition when administered systemically, although other routes of 
administration, topical or local, are permitted.
Glucocorticoid treatment entails significant cardiovascular effects. Indeed, chronic 
intake of synthetic glucocorticoids like prednisolone, methylprednisolone, triamci-
nolone or dexamethasone has been shown to increase blood pressure level (Whitworth 
et al. 1989; Brotman et al. 2006). Conversely, glucocorticoid deficiency is associated with 
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low blood pressure and vascular sensitivity to hormonal changes (Grunfeld and Eloy 
1987). In addition, the fludrocortisone is a glucocorticoid traditionally used as a treat-
ment for hypotension (Ong et al. 2013; Waeber and Pruvot 2013). However, discrepant 
results reported that corticosterone treatment for 4–6 days in control rats had no sig-
nificant effect on mean arterial pressure and HR (Scheuer and Bechtold 2002). Other 
authors also confirmed the lack of increase in systolic blood pressure in humans after 
administration of dexamethasone (a synthetic glucocorticoid with a higher activity than 
prednisone) at low dose (1 mg/day) and high dose (3 mg/day) during 4 days (Marquet 
et al. 1999).
Different mechanisms might account for an increase in blood pressure. Indeed, cor-
tisol administration (Connell et al. 1987) has been reported to increase plasma volume, 
extracellular fluid volume, exchangeable sodium and body weight. An increase in renal 
vascular resistances might be involved, although calculated total peripheral resistances 
are unchanged (Connell et al. 1987). Direct and indirect indexes of sympathetic activ-
ity were either unchanged or suppressed during cortisol administration, suggesting that 
cortisol-induced hypertension is not mediated by an increase in sympathetic tone (Kelly 
et al. 1998).
Overall, glucocorticoid excess is associated with hypertension in man and in ani-
mals (Grunfeld and Eloy 1987; Pirpiris et  al. 1993). Steroids-induced hypertension is 
independent of salt intake and can be prevented by glucocorticoid antagonists, such as 
RU486. Conversely, Grünfeld suggested that in some conditions, endogenous glucocorti-
coids contribute to the maintenance of blood pressure by enhancing vascular sensitivity 
to hormonal stimuli.
Accordingly, studies in animals showed that systemic elevations in glucocorticoids 
can modulate the arterial baroreflex effectiveness (Gardiner and Bennett 1983). Indeed, 
systemic administration of corticosterone modulates baroreflex control of both renal 
sympathetic nerve activity and heart rate, resulting in an increase in the arterial pres-
sure midpoint and decrease in the baroreflex sensitivity, independently of changes in 
arterial pressure in rats (Scheuer and Mifflin 2001; Scheuer and Bechtold 2002). These 
results in animal models support the hypothesis that glucocorticoid administration in 
human might decrease the baroreflex sensitivity. Although the relationships between 
glucocorticoids and cardiovascular diseases are complex, physiological changes induced 
by glucocorticoid intake, if confirmed, might precipitate some cardiovascular diseases 
(Whitworth et al. 1995).
Analyses of heart rate variability (HRV), blood pressure variability (SBPV) and barore-
flex sensitivity (BRS) have been used to assess the autonomic cardiovascular control, 
to predict cardiovascular morbidity (La Rovere et  al. 2001; Robinson et  al. 2003) and 
to evaluate overall cardiovascular health (Camm et  al. 1996). As a matter of interest, 
baroreflex gain is usually estimated by administration of vasoactive drugs (Pagani et al. 
1988) or pressure stimuli to the subject’s carotid baroreceptors with a neck collar (Ogoh 
et al. 2005). With these methods, substantial SBP and HR variabilities can be observed. 
Porta et al. (2000) suggested to remain cautious about these procedures, since they are 
based on non-physiological stimuli that may alter the actual baroreflex gain. Several 
techniques have been proposed to evaluate the baroreflex gain based on the spontane-
ous variability of SBP and HR. Among them, the spectral method allowed to investigate 
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the spontaneous interactions between HRV and SBPV with no any other physiologi-
cal or pharmacological maneuvers (Cottin et al. 2008; Porta et al. 2000). Therefore, this 
method should be particularly adequate to test the effect of a pharmacologic treatment 
on the baroreflex sensitivity such as glucocorticoid administration for instance.
To our knowledge, no study has investigated the effects of a 1-week administration of 
prednisone on the spontaneous baroreflex sensitivity. The aim of the present work was 
to analyze HRV, SBPV and BRS during a 1-week oral administration of glucocorticoids, 
in order to confirm the hypothesis that steroids can modify both systolic blood pressure 
level and BRS.
Methods
Twelve healthy male volunteers (age: 20.8 ±  1.2 years; weight: 73.3 ±  10.7 kg; height: 
178.5  ±  7.3  cm) were enrolled in the study. Before measurements, participants were 
familiarized with the experimental procedure and informed of the risks associated with 
the protocol. Ethics committee approval (No. 11-015, UFR STAPS Orsay, France) and 
written informed consent were obtained including the authorization to publish their 
data. This study was a part of a larger research protocol with blood samples, biome-
chanical measures (EMG, forceplate), local oxygen uptake measures (NIRS) and cardio-
vascular measures. Therefore, the protocol was drastically formatted and financed. To 
achieve all the measures we planned, only 12 subjects could have been involved. Only 
male subjects were involved to avoid the possibility of menstrual hormone interferences. 
They did not take any glucocorticoid or non-steroidal anti-inflammatory drug for at least 
6  months prior to the study. Subjects were asked to maintain their exercise routines, 
normal food intake and were required to avoid competitive strenuous situations, any 
caffeine and alcohol for 24 h prior to each experimental session.
The double-blind, randomized cross-over study consisted of two 1-week periods of 
treatment for each subject separated by a 4-week drug-free washout period: placebo 
(PLA) or prednisone (PRED). PLA (gelatin) and PRED (trade name: Cortancyl 20 mg, 
tablets, Sanofi-Aventis Laboratory, Paris) were packaged in identical capsules. Dur-
ing the experimental periods, the subjects took three capsules per day of either PLA or 
PRED (60 mg) at home, between 7 and 8 am, over 7 days. They were questioned about 
the treatment they thought they had received first and were unable to report any differ-
ence. In addition, to ensure that they exactly follow the prescription, subjects had to fill 
in a form each time they took their treatment. Each subject came four times at the hos-
pital on the second (PLA2 or PRED 2, acute effect) and seventh (PLA7 or PRED7, long-
term effect) day of each treatment period, 3 h after the capsules ingestion.
Data collection procedures
ECG was digitized and recorded with a PowerLab device (ADInstruments Ltd, AUS) 
with a sampling frequency of 1000 Hz. Beat to beat RR intervals were extracted from 
ECG using Chart7 pro soft (Chart7 pro, ADInstruments, AUS). Extrasystoles were man-
ually processed by averaging the short and long RR intervals respectively preceding and 
following the extrasystole.
A Finometer device (TNO, BMI, The Netherlands) was used to record blood pressure 
from a cuff placed on a middle finger. BP signal yielded by the Finometer device has been 
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previously experimentally validated during laboratory tests (Idema et  al. 1989; Imholz 
et al. 1991). The Finometer was connected to the PowerLab that digitized and sampled 
BP signal at 1000 Hz. The series of systolic blood pressure (SBP) were assessed using a 
detection technique provided with the Chart7 pro software.
Signals were recorded in a quiet room at the hospital at a constant temperature (22 °C). 
The subjects were supine and their breathing frequency was paced at 0.25  Hz during 
10 min via audio feedback.




The Smoothed Pseudo Wigner–Ville Distribution (SPWVD) was used to compute 
instantaneous components of HRV and SBP variability. It was performed with the car-
diovascular toolbox developed in the scientific environment SCILAB (INRIA, France). 
The SPWVD provides a continuous evaluation of the amplitude and frequency, giving 
a nearly “instantaneous” complex FFT spectrum for each beat, with a high resolution 
achieved by independent time and frequency smoothing. Then, according to the stand-
ards (Camm et al. 1996), the instantaneous time frequency components were computed 
in low (LF-RR and LF-SBP from 0.04 to 0.15 Hz) and high frequency (HF-RR and HF-
SBP from 0.15 to 0.4 HZ) bands of SBP variability and HRV. The spectral power was 
computed in LF and HF ranges (spectral components) by integrating the power spectral 
density (PSD) as following:
Baroreflex sensitivity (BRS)
The baroreflex sensitivity was assessed in LF (LF-BRS) and HF (HF-BRS) bands at rest. 
The spectral baroreflex sensitivity (BRS) is supported by the hypothesis of a linear 
relation between the input (BP) and output (RR) of the model. The degree of linearity 
between the two signals is estimated by the value of the coherence function. Ranging 
from 0 to 1, it was accepted that RR and SBP spectra had a reliable linear relationship 
when the coherence index was higher than 0.5 (Taylor and Eckberg 1996; de Boer et al. 
1985). Next, the averaged spectral gain in HF and LF bands was the modulus of the 
transfer function between RR and SBP spectra (Maestri et al. 1998; Mangin et al. 2001; 
Monti et al. 2002).
Statistics
Normality of data was examined by Kolmogorov–Smirnov test. When the data distri-
bution was normal the differences between treatments (PLA vs. PRED) and treatment 
duration (D2 vs. D7) were tested with a two way ANOVA for repeated measures (Sig-
mastat 3.5, Systat software inc., UK). All pairwise multiple comparison procedures are 
given with the Holm-Sidak method. When the data distribution was not normal, an 




PSD ·∆f and HF =
0.4∑
f=0.15
PSD ·∆f (ms2 or mm2Hg).
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Results
Treatment effect (PRED vs. PLA)
HR increased following prednisone treatment (PLA: 60.8 ± 10.5 vs. PRED: 65.8 ± 9.1 
beats min−1, p < 0.05, Table 1) and the power of performed test with α = 0.05 was 0.822. 
However, absolute (LFRR and HFRR) and normalised (LFnu, HF nu and LF/HF ratio) 
components of HRV were not different between PLA and PRED in both LF and HF 
bands (Table 1).
SBP (PLA: 108 ± 10 vs. PRED: 106 ± 14 mmHg, NS, Table 2), DBP (PLA: 71 ± 7 vs. 
PRED: 71 ± 7 mmHg, NS, Table 2) and absolute SBPV components in the both LF and 
HF band did not change following prednisone administration (Table 2).
BRS was not different between treatment conditions in both LF and HF band (Table 3).
Duration of the treatment (D2 vs. D7)
HR, absolute and normalised HRV components did not change between D2 and D7 
(Table 1).
SBP and HF-SBP amplitude did not change (Table  2) whereas LF-SBP amplitude 
increased between D2 and D7 (D2: 2.71 ± 0.89 vs. D7: 3.87 ± 0.6 mmHg, p = 0.037, 
Table  2) and the power of performed test with α =  0.05 was 0.499. On D2, post hoc 
Table 1 Combined effects of  the prednisone treatment (placebo vs. prednisone) and  the 
treatment duration (Day 2 vs. Day 7) on  heart rate (HR) and  HR variability, expressed 
in  absolute (low frequency: LFRR and  high frequency amplitude: HFRR) and  normalized 
(LFnu, HFnu and LF/HF) components
LFnu = LFRR/(LFRR + HFRR) and HFnu = HFRR/(LFRR + HFRR). Data are expressed as mean ± SD
1 P < 0.05 vs prednisone
Placebo Prednisone
Day 2 Day 7 Day 2 Day 7
HR (bpm) 59.0 ± 8.41 62.7 ± 12.3 66.9 ± 9.2 64.8 ± 9.4
LFRR (ms) 34.0 ± 8.6 30.8 ± 7.7 31.9 ± 17.2 30.8 ± 13.8
HFRR (ms) 57.0 ± 33.7 49.4 ± 38.1 44.5 ± 32.4 49.5 ± 35.9
LFnu 0.41 ± 0.12 0.45 ± 0.14 0.45 ± 0.10 0.42 ± 0.12
HFnu 0.59 ± 0.12 0.55 ± 0.14 0.55 ± 0.10 0.58 ± 0.12
LF/HF ratio 0.76 ± 0.41 0.90 ± 0.47 0.87 ± 0.29 0.80 ± 0.37
Table 2 Combined effects of  the prednisone treatment (placebo vs. prednisone) and  the 
treatment duration (Day 2 vs. Day 7) on systolic (SBP), diastolic (DBP), mean (MBP) blood 
pressure and  SBP variability components: amplitude in  low (LFSBP) and  high frequency 
(HFSBP)
Data expressed as mean ± SD
1 P < 0.05 vs prednisone
2 P < 0.05 vs Day 7
Placebo Prednisone
Day 2 Day 7 Day 2 Day 7
SBP (mmHg) 107 ± 12 109 ± 10 107 ± 15 105 ± 14
LFSBP (mmHg) 2.34 ± 0.511 2.74 ± 1.50 3.08 ± 1.052 3.99 ± 1.75
HFSBP (mmHg) 1.10 ± 0.47 1.17 ± 0.42 1.42 ± 0.38 1.24 ± 0.33
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statistics revealed that LF-SBP was higher with PRED than PLA (D2: 3.09 ± 0.19 vs. D7: 
2.34 ± 0.19, p < 0.041).
BRS was not different between D2 and D7 in both LF and HF band (Table 3).
Discussion
To our knowledge, the effects of 1-week administration of prednisone on spontaneous 
baroreflex sensitivity and cardiovascular variability in young subjects have never been 
investigated. The main results of this study is that 7 days of administration increased HR 
and the LF component of the SBPV whereas no change in SBP level was observed.
Regarding the SBP, the literature reports conflicting results about the effect of gluco-
corticoid treatment on systolic blood pressure; some studies observed an increase in SBP 
in rats (Scheuer and Bechtold 2002) and humans (Whitworth et al. 1989) whereas other 
did not (Marquet et al. 1999). In the present study, pharmacological treatment with the 
administration of 60 mg per day of prednisone during 7 days did not increase systolic 
blood pressure (SBP). This result is in accordance with a study by Marquet et al. (1999) 
who investigated the effect of dexamethasone (a synthetic glucocorticoid with a higher 
activity than prednisone) at low (1 mg/day) and high doses (3 mg/day) during 4 days on 
the cardiovascular system. As in our study, steroid administration did not change SBP 
whatever the dosage. Conversely, a significant increase in SBP was observed (Brotman 
et  al. 2006) following higher doses of dexamethasone (6  mg/day for 5  days). Accord-
ing to correspondence tables for glucocorticoids (Meikle and Tyler 1977), 60 mg/day of 
prednisone would correspond to 9 mg/day of dexamethasone. Therefore, our dosage of 
prednisone should have produced stronger effects than the dexamethasone treatment 
administered in both of the above cited studies (Brotman et  al. 2006; Marquet et  al. 
1999). In addition, differences in the methods used to measure blood pressure might 
account for this discrepancy. Indeed, BP results were the average of three punctual 
measurements in the two previous articles (Brotman et  al. 2006; Marquet et  al. 1999) 
whereas more accurate results are expected from the continuous, 10 min BP recording 
used in the present study.
The second interesting finding was that prednisone administration provoked both 
increase in HR and in LF-SBPV. The increase in HR could be due to a decrease in 
the vagal control or an increase in the sympathetic control of HR. The power of per-
formed test with α = 0.05 was 0.822 suggesting the effect of the prednisone on HR was 
Table 3 Combined effects of  the prednisone treatment (placebo vs. prednisone) and  the 
treatment duration (Day 2 vs. Day 7) on the baroreflex sensitivity (BRS) indexes
Data are expressed as mean ± SD
There is no significant difference
Placebo Prednisone
Day 2 Day 7 Day 2 Day 7
LF BRS gain (ms/mmHg) 15.32 ± 5.2 11.33 ± 7.3 11.07 ± 6.42 9.03 ± 5.19
LF Coherence 0.62 ± 0.06 0.63 ± 0.10 0.65 ± 0.06 0.67 ± 0.09
HF BRS gain (ms/mmHg) 43.58 ± 24.56 36.22 ± 24.09 29.24 ± 21.41 35.00 ± 25.24
HF coherence 0.70 ± 0.07 0.70 ± 0.05 073 ± 0.04 0.68 ± 0.03
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statistically strong. In this latter context, LF-SBP is only mediated by the sympathetic 
branch of the cardiovascular control. Therefore, the combination of this increase in both 
HR and LF-SBP suggests an increase in the sympathetic branch of the autonomic cardio-
vascular control (Pagani et al. 1986). Such an increase in resting condition might have 
deleterious effect in cardiac health (Camm et al. 1996; La Rovere et al. 2001). However, 
with a power of performed test with α = 0.05 was 0.499, the difference in LF-SBP was 
not very strong. In addition, the prednisone treatment did not provoke any increase in 
SBP and the above results were not in accordance with other studies (Brotman et  al. 
2006; Marquet et al. 1999) which found either a decrease or no change in HR. Therefore, 
it would be speculative to conclude that the treatment of prednisone entailed an increase 
in the sympathetic cardiovascular control which would have a deleterious effect on sub-
ject’s health.
Finally, a recent study has analyzed the spontaneous BRS during exhaustive dynamic 
exercise (Cottin et al. 2008) and it would worth investigating the effects of glucocorticoid 
intake on the BRS during this type of exercise in order to evaluate the benefit-risk ratio 
of such treatment.
Conclusion
Seven days administration of glucocorticoids (prednisone 60  mg/day) did not change 
the systolic blood pressure level in young adults. However, a slight increase in both HR 
and LF-SBPV were observed suggesting a potential sympathetic cardiovascular stimulus. 
Although we found a significant effect of the 1-week prednisone treatment on heart rate 
and low frequency power of systolic blood pressure variability, we reported neither an 
increase in the systolic blood pressure level nor a decrease in the baroreflex sensitiv-
ity. Therefore, the fragility of our results cannot support a deleterious effect of 1-week 
administration of prednisone on the autonomic cardiovascular control which might be 
involved in cardiovascular diseases.
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